Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:~* Smoking history of at least 10 pack-years~* Post-bronchodilator FEV1 \< 80% and ≥ 30% of the predicted normal value~* Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%~Exclusion Criteria:~1. Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1~2. Patients with concomitant pulmonary disease~3. Patients with a history of asthma~4. Any patient with lung cancer or a history of lung cancer~5. Patients with a history of certain cardiovascular comorbid conditions~6. Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency~7. Patients in the active phase of a supervised pulmonary rehabilitation program~8. Patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glycopyrronium bromide (Type: EXPERIMENTAL): Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).